Post-Kala-Azar Dermal Leishmaniasis Without Previous History of Visceral Leishmaniasis.
Post-kala-azar dermal leishmaniasis (PKDL) without previous visceral leishmaniasis (VL) is a rare dermatological manifestation of Leishmania infection. To date, most of the reported cases neither showed parasitological confirmation nor explained the outcome of treatment. Herein, we report three confirmed cases that were were successfully cured after miltefosine treatment.
Centre for Clinical Epidemiology and Biostatistics (CCEB), School of Medicine and Public Health, Faculty of Health and Medicine, The University of Newcastle (UoN), New South Wales, Australia.|Nutrition and Clinical Services Division (NCSD), International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Golam
G
Hasnain
Nutrition and Clinical Services Division (NCSD), International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Mohammad Sohel
MS
Shomik
Nutrition and Clinical Services Division (NCSD), International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Prakash
P
Ghosh
Nutrition and Clinical Services Division (NCSD), International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Mamun Or
MO
Rashid
Nutrition and Clinical Services Division (NCSD), International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Shakhawat
S
Hossain
Department of Parasitology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan.
Shinjiro
S
Hamano
Nutrition and Clinical Services Division (NCSD), International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh. din63d@icddrb.org.
Dinesh
D
Mondal
D000293:Adolescent; D000328:Adult; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D016054:DNA, Protozoan / Q000302:isolation & purification; D005260:Female; D006801:Humans; D007893:Leishmania donovani / Q000235:genetics; D016773:Leishmaniasis, Cutaneous / Q000150:complications*; D007898:Leishmaniasis, Visceral / Q000150:complications*; D008297:Male; D010767:Phosphorylcholine / Q000031:analogs & derivatives / Q000627:therapeutic use; D016133:Polymerase Chain Reaction
D000981:Antiprotozoal Agents; D016054:DNA, Protozoan; D010767:Phosphorylcholine; C039128:miltefosine
Br J Dermatol. 2011 Aug;165(2):411-4
21561437
PLoS Negl Trop Dis. 2014 Aug 21;8(8):e3020
25144317
ScientificWorldJournal. 2015;2015:414378
25685839
PLoS Negl Trop Dis. 2010 Oct 05;4(10):null
20957193
Lancet. 1990 Sep 22;336(8717):750
1975920
Trop Med Int Health. 2013 Jan;18(1):96-100
23136856
Am J Trop Med Hyg. 2013 Aug;89(2):345-53
23817330
BMC Public Health. 2015 Oct 26;15:1092
26503551
Clin Microbiol Infect. 2014 Jun;20(6):O374-83
24237596
Clin Infect Dis. 2010 Jan 1;50(1):73-6
19951168
Lancet Infect Dis. 2003 Feb;3(2):87-98
12560194
Braz J Infect Dis. 2013 Sep-Oct;17(5):610-2
24012431